AGIO Agios Pharmaceuticals, Inc.

41.55
+0  (0%)
Previous Close 41.55
Open 41.61
Price To book 4.35
Market Cap 1.75B
Shares 42,014,000
Volume 380,451
Short Ratio 6.63
Av. Daily Volume 828,586

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17518692
  2. 8-K - Current report 17515839
  3. 8-K - Current report 17506322
  4. 8-K - Current report 162054089
  5. 8-K - Current report 162035187

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing due by end of 2017.
AG-120
IDH1m Relapsed/Refractory AML - cancer
Phase 2 first data released at EHA meeting June 2016. Pivotal trial to be initiated mid-2018.
AG-348
Pyruvate kinase deficiency
Phase 3 to be initiated 1H 2017
AG-120 and VIDAZA
Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer
Global Phase 3 study for AG-221 initiated October 2015. Continue to enrol through 2016
AG-221 - IDHENTIFY
Refractory Acute myeloid leukemia (AML) - cancer
NDA filed December 2016.
AG-221
Advanced hematologic malignancies with an IDH2 mutation
Phase 2 initiated December 2016.
AG-120
IDH1 mutant positive cholangiocarcinoma - cancer

Latest News

  1. Falling Earnings Estimates Signal Weakness Ahead for Agios Pharmaceuticals (AGIO)
  2. Why Agios Pharmaceuticals Sank 34.4% in 2016
  3. AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure
  4. Agios Announces Key Upcoming Milestones to Support Evolution to a Commercial Stage Biopharmaceutical Company in 2017
  5. AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
  6. Shire, Agios add former Genentech CEO as board member
  7. Agios Appoints Ian Clark to Board of Directors
  8. Agios Appoints Ian Clark to Board of Directors
  9. Agios to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017
  10. Agios Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AGIO) : December 20, 2016
  11. Agios Stops Development of PKR Activator AG-519, Stock Falls
  12. Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : December 19, 2016
  13. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Shareholders of Agios Pharmaceuticals, Inc. - AGIO
  14. Why Agios Pharmaceuticals Inc. Got Hammered Today
  15. Agios Pharma Shares Crushed Under Weight Of Clinical Setback
  16. INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Agios Pharmaceuticals, Inc. and Certain Officers and Directors -- AGIO
  17. Gilead Must Pay Merck $2.5 Billion For Hep C Patent; Agios Stock Anemic
  18. Agios Pharma shares dive after anemia treatment development halted
  19. AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  20. Agios drops drug for blood disorder due to side effects

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17518692
  2. 8-K - Current report 17515839
  3. 8-K - Current report 17506322
  4. 8-K - Current report 162054089
  5. 8-K - Current report 162035187
  6. 8-K - Current report 162006479
  7. 8-K - Current report 161984820
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 161971729
  9. 8-K - Current report 161970132
  10. CT ORDER - Confidential treatment order 161895031